The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition

Muhammad Saad MD, Umut Gomceli MD, Pranav Ravi MD, Andrisael G Lacoste MD, Neil Shah MD, Timothy J Vittorio MD

Abstract

Heart failure (HF) is one of the leading causes of hospital readmissions and health care expenditures. With a vast degree of advancements in the clinical approach and diagnosis, its management protocol is limited in terms of enhancing quality of life and prognosis. Type 2 diabetes mellitus (T2DM) is considered as one of the commonly associated comorbid conditions in the HF population. The understanding of the molecular and metabolic models of HF has led to the utilization of therapeutic goals of T2DM in improving HFrelated complications. In the recent era, SGLT-2 inhibitors have shown success in decreasing cardiovascular mortality in the T2DM population. This article will help the reviewer to comprehend the pathophysiology of HF and the potential role of SGLT-2 inhibitors in the management algorithm of HF and its associated risk factors in T2DM.

Article Details

Article Type

Review

DOI

10.7573/dic.212549

Publication Dates

Accepted: ; Published: .

Citation

Saad M, Gomceli U, Ravi P, Lacoste AG, Shah N, Vittorio TJ. The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition. Drugs in Context 2018; 7: 212549. DOI: 10.7573/dic.212549

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.